Posted by Michael Wonder on 16 Dec 2020
Fortress Biotech announces breakthrough therapy designation for CUTX-101, copper histidinate, for the treatment of Menkes disease
15 December 2020 - Rolling submission of new drug application to the FDA for CUTX-101 on track to begin in the first quarter of 2021 and to be completed by the end of the second quarter of 2021.
Fortress Biotech today announced that the U.S. FDA has granted breakthrough therapy designation to Cyprium Therapeutics for CUTX-101, a potential treatment for Menkes disease.
